Related Experiment Video
Updated: Jun 8, 2026

Imaging ATG9A, a Multi-Spanning Membrane Protein
Published on: June 16, 2023
Autotaxin: a protein with two faces
Mousumi Tania1, Md Asaduzzaman Khan, Huaiyuan Zhang
1Department of Biochemistry, School of Biological Science and Technology, Central South University, Changsha, Hunan 410013, China.
Autotaxin (ATX) enzyme impacts cancer by stimulating cell growth and migration via lysophosphatidic acid (LPA). However, ATX also produces cyclic phosphatidic acid (cPA), which inhibits cancer progression, making ATX a potential therapeutic target.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Research
Background:
- Autotaxin (ATX) is an enzyme with lysophospholipase D activity, crucial for cellular membrane lipid metabolism.
- ATX has been implicated in cancer progression, promoting tumor cell proliferation, motility, and angiogenesis.
- Its product, lysophosphatidic acid (LPA), is a potent mitogen involved in various cellular processes.
Purpose of the Study:
- To explore the dual role of Autotaxin (ATX) in cancer biology.
- To investigate the impact of ATX-produced lysophosphatidic acid (LPA) and cyclic phosphatidic acid (cPA) in tumorigenesis.
- To evaluate ATX as a potential therapeutic target for cancer treatment.
Main Methods:
- Enzyme activity assays to measure lysophospholipase D activity.
- Cell-based assays to assess cancer cell proliferation and migration.
- Analysis of signaling pathways involved in ATX-mediated cancer progression.
- Investigation of cPA's effects on cell cycle regulation and metastasis.
Main Results:
- ATX significantly promotes cancer cell proliferation and tumor cell motility through LPA production.
- ATX also catalyzes the formation of cyclic phosphatidic acid (cPA), which exhibits antitumor properties.
- cPA has demonstrated antimitogenic effects, regulating the cell cycle and inhibiting cancer invasion and metastasis.
- LPA and cPA production by ATX can be modulated under various physiological conditions.
Conclusions:
- Autotaxin (ATX) exhibits a dual role in cancer, acting as both an oncogenic factor and a producer of tumor-suppressive molecules.
- The ability to manipulate ATX's enzymatic products, LPA and cPA, presents a promising therapeutic strategy for cancer treatment.
- Targeting ATX offers a novel approach for developing anticancer therapies by modulating its lipid-modifying activities.
Related Concept Videos
Tail-anchoring of Proteins in the ER Membrane
Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
The ADP/ATP Carrier Protein
Single-pass Transmembrane Proteins
Insertion of Multi-pass Transmembrane Proteins in the RER
The multipass transmembrane proteins are the type IV integral membrane proteins with multiple topogenic sequences determining their spatial arrangement in the ER membrane. Nearly all multipass proteins lack a cleavable signal sequence and use...
Translocation of Proteins into the Mitochondria
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...

